Detalhe da pesquisa
1.
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
J Neurol Neurosurg Psychiatry;
95(2): 134-141, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37558400
2.
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
J Neurol Neurosurg Psychiatry;
95(2): 125-133, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37748927
3.
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study.
Eur J Neurol;
: e16331, 2024 May 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38794973
4.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Ann Neurol;
87(5): 688-699, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32056253
5.
Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry.
Metabolomics;
16(2): 26, 2020 02 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32052189
6.
Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Mult Scler;
26(12): 1532-1539, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31392923
7.
Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
Acta Neurol Scand;
139(5): 462-468, 2019 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30740668
8.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Ann Neurol;
79(6): 950-8, 2016 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27038238
9.
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary.
Mult Scler;
28(8): 1177-1178, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35678609
10.
Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.
Mult Scler;
23(9): 1249-1257, 2017 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27780912
11.
Brain parenchymal fraction in an age-stratified healthy population - determined by MRI using manual segmentation and three automated segmentation methods.
J Neuroradiol;
43(6): 384-391, 2016 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27720265
12.
How to minimize the risk for headache? A lumbar puncture practice questionnaire study.
Ideggyogy Sz;
69(11-12): 397-402, 2016 Nov 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29733557
13.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Mult Scler;
21(1): 48-56, 2015 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24866201
14.
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Mult Scler;
21(8): 1036-44, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25392339
15.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
J Neurol Neurosurg Psychiatry;
85(10): 1116-21, 2014 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24554104
16.
Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
Mult Scler;
20(8): 1095-101, 2014 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24378984
17.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Mult Scler;
20(1): 43-50, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23702432
18.
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab.
Mult Scler J Exp Transl Clin;
10(2): 20552173241252566, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38807848
19.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
Mult Scler;
19(5): 622-30, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23012254
20.
Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.
Brain Commun;
5(1): fcad011, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36756308